Jerome M. Hauer - 25 May 2023 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Reporting relationship: Director
Issuer ticker: EBS
Reported as of: 25 May 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 May 2023, 19:08:39 UTC
Prior SEC filing: 31 May 2022
Source filing: View source filing
Reporting owner signature: /s/ Richard S. Lindahl, Attorney-in-fact

Key filing fact

Jerome M. Hauer filed Form 4 for Emergent BioSolutions Inc. (EBS) on 30 May 2023.

Key facts

This page summarizes Jerome M. Hauer's Form 4 filing for Emergent BioSolutions Inc. (EBS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 30 May 2023, 19:08.

Change

Previous filing in this sequence was filed on 31 May 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EBS transaction

Common Stock

Award

Transaction value: $0
Shares: +33,847
Change %: +143%
Price: $0.000000
Shares after: 57,508
Date: 25 May 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Consists of restricted stock units granted under the company's Stock Incentive Plan, as amended and restated. These restricted stock units vest in one installment beginning on the day prior to the first anniversary of the date of grant assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.